Biotech Values

[genisi]

what those data mean for BLUE

That the old vector had a low transduction efficiency and as far as I can tell the current one has better titer and potency. Stability and durability are fine so far, for both vectors. If the patient had not been such a severe one, even the weaker vector could probably do better and longer.
Think the "GT nightmare scenario" is possible insertional oncogenesis more than low transgene expression.